Gabapentin In Pregnancy And The Risk Of Adverse Neonatal ... - PLOS

Citation: Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, et al. (2020) Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med 17(9): e1003322. https://doi.org/10.1371/journal.pmed.1003322

Academic Editor: Sarah J. Stock, University of Edinburgh, UNITED KINGDOM

Received: September 9, 2019; Accepted: July 30, 2020; Published: September 1, 2020

Copyright: © 2020 Patorno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: Because of the data use agreement in place, the research team cannot share the database used for the current paper, which was based on Medicaid, a joint federal and state program that helps provide healthcare coverage for people with low incomes and limited resources in the United States. Other researchers may request to gain access to the Medicaid database through the Research Data Assistance Center (ResDAC) (https://www.resdac.org/).

Funding: This study was supported by an R01 grant (R01 MH100216) from the National Institute of Mental Health. EP is supported by a career development grant K08AG055670 from the National Institute on Aging. BTB was supported by a career development grant K08HD075831 from the National Institute Of Child Health & Human Development of the National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Competing interests: We have read the journal's policy and the authors of this manuscript have the following competing interests: EP is investigator of an investigator-initiated grant to the Brigham and Women’s Hospital from Boehringer Ingelheim, not related to the topic of the submitted work. SH-D has consulted for Boehringer-Ingelheim and UCB for unrelated topics and has worked with the AED pregnancy registry, which is funded by multiple companies. KFH, BTB, and SH-D have been investigators on grants to the Brigham and Women’s Hospital from Lilly, GSK, and Pfizer and BTB on grants from Baxalta and Pacira, unrelated to the topic of this manuscript. BTB consults for Aetion for unrelated projects and was a consultant on a postpartum hemorrhage quality improvement project sponsored by a grant from Merck for Mothers. RJD reports grants from Merck, outside the submitted work.

Abbreviations: ACE, angiotensin-converting enzyme; ARR, apparent relative risk; CI, confidence interval; FDA, United States Food and Drug Administration; GABA, gamma-aminobutyric acid; hdPS, high-dimensional propensity score; LMP, last menstrual period; MAX, United States Medicaid Analytic eXtract; NICUa, neonatal intensive care unit admission; PS, propensity score; RR, relative risk; SGA, small for gestational age; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; T1, first trimester